Drugs / Tumor Specific Antigen-loaded Dendritic Cells
Tumor Specific Antigen-loaded Dendritic Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT03185429 | Dec 2017 → Dec 2018 | colorectal neoplasm, gastric neoplasm | BGI, China | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tumor Specific Antigen-loaded Dendritic Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03185429 ↗ |
| Modality | Cell therapy | “autologous TSA-DC cell” NCT03185429 ↗ |
| Route | Subcutaneous | “Subjects will be given subcutaneous injection of 5.0x10\^6-1.0x10\^7 TSA-DC on week 1,3,5,11,17,23,35,47.” NCT03185429 ↗ |